RhumbLine Advisers
ATRA icon

RhumbLine Advisers’s Atara Biotherapeutics ATRA Stock Holding History

RhumbLine Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-175
Closed -$827 – 4144
2026
Q1 		$827 Hold
175
– – ﹤0.01% 3992
2025
Q4 		$3.17K Hold
175
– – ﹤0.01% 3951
2025
Q3 		$2.51K Hold
175
– – ﹤0.01% 3969
2025
Q2 		$1.35K Hold
175
– – ﹤0.01% 4019
2025
Q1 		$1.04K Hold
175
– – ﹤0.01% 4029
2024
Q4 		$2.33K Hold
175
– – ﹤0.01% 4029
2024
Q3 		$1.42K Sell
175
-507
-74% -$4.34K ﹤0.01% 4077
2024
Q2 		$5.8K Sell
682
-5,221
-88% -$78.5K ﹤0.01% 4060
2024
Q1 		$102K Buy
5,903
+86
+1% +$1.53K ﹤0.01% 3441
2023
Q4 		$74.6K Sell
5,817
-2
-0% -$47 ﹤0.01% 3540
2023
Q3 		$215K Buy
5,819
+108
+2% +$4.81K ﹤0.01% 3123
2023
Q2 		$230K Sell
5,711
-184
-3% -$10.4K ﹤0.01% 3168
2023
Q1 		$427K Buy
5,895
+173
+3% +$16.8K ﹤0.01% 2492
2022
Q4 		$469K Buy
5,722
+54
+1% +$5.63K ﹤0.01% 2492
2022
Q3 		$536K Buy
5,668
+101
+2% +$11.3K ﹤0.01% 2468
2022
Q2 		$1.08M Buy
5,567
+793
+17% +$129K ﹤0.01% 2098
2022
Q1 		$1.11M Sell
4,774
-350
-7% -$111K ﹤0.01% 2092
2021
Q4 		$2.02M Buy
5,124
+83
+2% +$34.9K ﹤0.01% 1878
2021
Q3 		$2.26M Sell
5,041
-40
-0.8% -$14.3K ﹤0.01% 1845
2021
Q2 		$1.98M Buy
5,081
+436
+9% +$156K ﹤0.01% 1954
2021
Q1 		$1.67M Sell
4,645
-257
-5% -$114K ﹤0.01% 1989
2020
Q4 		$2.41M Buy
4,902
+615
+14% +$284K ﹤0.01% 1763
2020
Q3 		$1.39M Buy
4,287
+42
+1% +$14.3K ﹤0.01% 1866
2020
Q2 		$1.55M Buy
4,245
+1,295
+44% +$327K ﹤0.01% 1866
2020
Q1 		$628K Buy
2,950
+161
+6% +$51.1K ﹤0.01% 2071
2019
Q4 		$1.15M Buy
2,789
+66
+2% +$22.8K ﹤0.01% 2016
2019
Q3 		$961K Buy
2,723
+254
+10% +$94.8K ﹤0.01% 2049
2019
Q2 		$1.24M Buy
2,469
+261
+12% +$184K ﹤0.01% 1973
2019
Q1 		$2.19M Sell
2,208
-44
-2% -$40.9K ﹤0.01% 1653
2018
Q4 		$1.96M Buy
2,252
+762
+51% +$708K ﹤0.01% 1655
2018
Q3 		$1.54M Sell
1,490
-80
-5% -$78.2K ﹤0.01% 1801
2018
Q2 		$1.44M Buy
1,570
+227
+17% +$244K ﹤0.01% 1850
2018
Q1 		$1.31M Buy
1,343
+255
+23% +$232K ﹤0.01% 1825
2017
Q4 		$492K Sell
1,088
-176
-14% -$65K ﹤0.01% 2234
2017
Q3 		$523K Buy
1,264
+9
+0.7% +$3.39K ﹤0.01% 2287
2017
Q2 		$439K Buy
1,255
+127
+11% +$48.9K ﹤0.01% 2368
2017
Q1 		$579K Buy
1,128
+34
+3% +$14.1K ﹤0.01% 2184
2016
Q4 		$388K Sell
1,094
-12
-1% -$5.08K ﹤0.01% 2356
2016
Q3 		$592K Buy
1,106
+40
+4% +$21.7K ﹤0.01% 2099
2016
Q2 		$600K Buy
1,066
+374
+54% +$180K ﹤0.01% 2087
2016
Q1 		$329K Sell
692
-3
-0.4% -$1.35K ﹤0.01% 2482
2015
Q4 		$459K Buy
695
+134
+24% +$101K ﹤0.01% 2296
2015
Q3 		$441K Buy
561
+65
+13% +$79.3K ﹤0.01% 2317
2015
Q2 		$654K Buy
+496
New +$569K ﹤0.01% 2151

Other funds holding ATRA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's ATRA Position: Q2 2026 in Review

RhumbLine Advisers sold out of Atara Biotherapeutics (ATRA) in Q2 2026, closing a stake of 175 shares — an estimated $827 sold.

RhumbLine Advisers first reported a position in ATRA in Q2 2015 and held it in 44 quarters. The position peaked at $2.41M in Q4 2020. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • RhumbLine Advisers reported no remaining Atara Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • RhumbLine Advisers sold 175 Atara Biotherapeutics shares in Q2 2026, an estimated $827.
  • RhumbLine Advisers first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 44 quarters.
  • RhumbLine Advisers's Atara Biotherapeutics position peaked at $2.41M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.